Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, Southwest Hospital, Army Medical University, Chongqing, China.
Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, Southwest Hospital, Army Medical University, Chongqing, China.
Clinics (Sao Paulo). 2024 Jul 24;79:100429. doi: 10.1016/j.clinsp.2024.100429. eCollection 2024.
The Angiographic Microvascular Resistance (AMR), derived from a solitary angiographic view, has emerged as a viable substitute for the Index of Microcirculatory Resistance (IMR). However, the prognostic significance in ST-Segment Elevation Myocardial Infarction (STEMI) patients is yet to be established. This research endeavors to explore the prognostic capabilities of AMR in patients diagnosed with STEMI.
In this single-center, retrospective study, 232 patients diagnosed with STEMI who received primary Percutaneous Coronary Intervention (PCI) were recruited from January 1, 2018, to June 30, 2022. Utilizing the maximally selected log-rank statistics analysis, participants were divided into two cohorts according to an AMR threshold of 2.55 mmHg*s/cm. The endpoint evaluated was a composite of all-cause mortality or hospital readmission due to heart failure.
At a median follow-up of 1.74 (1.07, 3.65) years, the composite endpoint event was observed in 28 patients within the higher AMR group and 8 patients within the lower AMR group. The higher AMR group showed a significantly higher risk for composite outcome compared to those within the low-AMR group (HR: 3.33; 95% CI 1.30‒8.52; p = 0.03). AMR ≥ 2.55 mmHg*s/cm was an independent predictor of the composite endpoint (HR = 2.33; 95% CI 1.04‒5.21; p = 0.04). Furthermore, a nomogram containing age, sex, left ventricle ejection fraction, post-PCI Quantitative Flow Ratio (QFR), and AMR was developed and indicated a poorer prognosis in the high-risk group for STEMI patients at 3 years. (HR=4.60; 95% CI 1.91‒11.07; p < 0.01).
AMR measured after PCI can predict the risk of all-cause death or readmission for heart failure in patients with STEMI. AMR-involved nomograms improved predictive performance over variables alone.
从单一血管造影角度得出的血管造影微血管阻力(AMR)已成为微血管阻力指数(IMR)的可行替代品。然而,其在 ST 段抬高型心肌梗死(STEMI)患者中的预后意义尚未确定。本研究旨在探讨 AMR 在 STEMI 患者中的预后能力。
在这项单中心回顾性研究中,我们招募了 2018 年 1 月 1 日至 2022 年 6 月 30 日期间接受直接经皮冠状动脉介入治疗(PCI)的 232 例 STEMI 患者。利用最大选择对数秩统计分析,根据 AMR 阈值 2.55 mmHg*s/cm 将参与者分为两组。评估终点为全因死亡率或因心力衰竭再次住院的复合终点事件。
在中位数为 1.74(1.07,3.65)年的随访中,较高 AMR 组中有 28 例患者和较低 AMR 组中有 8 例患者出现复合终点事件。与低 AMR 组相比,较高 AMR 组的复合结局风险显著更高(HR:3.33;95%CI 1.30‒8.52;p = 0.03)。AMR≥2.55 mmHg*s/cm 是复合终点的独立预测因素(HR=2.33;95%CI 1.04‒5.21;p=0.04)。此外,我们还开发了一个包含年龄、性别、左心室射血分数、PCI 后定量血流比率(QFR)和 AMR 的列线图,该列线图表明,对于 STEMI 患者,3 年内 AMR 较高的高危组预后较差(HR=4.60;95%CI 1.91‒11.07;p<0.01)。
PCI 后测量的 AMR 可预测 STEMI 患者全因死亡或因心力衰竭再次住院的风险。包含 AMR 的列线图比单独的变量提高了预测性能。